InvestorsHub Logo

Real McCoy

09/26/22 9:29 PM

#130683 RE: MadScholar1 #130682

This is freakin hilarious!!!!!!

THEDOG 17

09/26/22 9:36 PM

#130684 RE: MadScholar1 #130682

Yes exactly who does that? No one! Good Things Are Coming Very Very Very Soon!

trader59

09/26/22 9:37 PM

#130685 RE: MadScholar1 #130682

You don't go through 2 bidding processes, the 2nd one being a liquidation, accept a bid, get court approval for the bid, close the transaction, document all of that in the court records, distribute the funds from that transaction and the other collections to the creditors, and close the proceedings with that being a hoax. That isn't a "PR," those are court records and the absolute facts. Those "discrepancies" were carefully selected and pieced together snippets used to distort the very clear and direct reading of the records and fabricate an alternate reality of a buyout that was false, all to flip the stock of this company for profit. That is something that happens every day on the OTC, and it happened on BIOAQ. The court records are the facts, the company was liquidated and shut down.
Not one single word directly from the company in over 4 years, the last one being the resignation of the directors and officers of the company.
And anybody believing that crap about the moon landing not being real doesn't need to be doing their own investing, especially in the OTC. CD's have pretty good rates right now.

iron-eagle

09/26/22 11:14 PM

#130687 RE: MadScholar1 #130682

You want to read some good Bioamber info as it relates to this whole ball of wax? Head over to LCY Group's LinkedIn page. I've been busy reading some post over there. Much more entertaining and informative. I find it incredibly amazing that LCY "bought" that beautiful Bioamber plant in Sarnia and is now buying BioSa from China and having it shipped into the US. What is obvious from the post on LinkedIn is that they are having a hard time retaining employees and it most likely stems from the management style. Anyways the discrepancies in the Bioamber case are noteworthy. No transaction for the shares ---- forecast fees for the sale of the Company. It's like PwC had unrelated parties write each report on Bioamber lol. I'll keep you posted.

IE